Obesity and Atrial Fibrillation: Therapeutic Perspective for GLP-1 Analogs

Abstract

Obesity is a well-established risk factor for the development of atrial fibrillation, and weight reduction has a beneficial effect on the natural course of the arrhythmia. In light of reports suggesting the positive impact of glucagon-like peptide-1 analogs on various metabolic parameters, especially weight reduction, they may potentially represent an effective therapeutic option for patients with atrial fibrillation. Preclinical studies indicate that GLP-1 analogs decrease susceptibility to atrial fibrillation by improving electrophysiological and structural parameters of the heart, however, clinical research outcomes provide conflicting results. The review article discusses the influence of obesity and weight reduction on the risk of atrial fibrillation development, as well as the role of GLP-1 analogs in the treatment of the arrhythmia.